Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBT Margin (2017 - 2025)

Historic EBT Margin for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to 14.03%.

  • Organogenesis Holdings' EBT Margin rose 89700.0% to 14.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.33%, marking a year-over-year increase of 19300.0%. This contributed to the annual value of 0.58% for FY2024, which is 29800.0% down from last year.
  • Latest data reveals that Organogenesis Holdings reported EBT Margin of 14.03% as of Q3 2025, which was up 89700.0% from 11.72% recorded in Q2 2025.
  • Organogenesis Holdings' 5-year EBT Margin high stood at 17.19% for Q2 2021, and its period low was 29.74% during Q1 2025.
  • In the last 5 years, Organogenesis Holdings' EBT Margin had a median value of 7.04% in 2023 and averaged 2.6%.
  • Per our database at Business Quant, Organogenesis Holdings' EBT Margin soared by 362600bps in 2021 and then plummeted by -257900bps in 2025.
  • Over the past 5 years, Organogenesis Holdings' EBT Margin (Quarter) stood at 14.77% in 2021, then tumbled by -49bps to 7.58% in 2022, then crashed by -124bps to 1.8% in 2023, then skyrocketed by 549bps to 8.1% in 2024, then skyrocketed by 73bps to 14.03% in 2025.
  • Its EBT Margin stands at 14.03% for Q3 2025, versus 11.72% for Q2 2025 and 29.74% for Q1 2025.